Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S2724-5691.21.08925-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fumarprotocetraric acid and geraniin were identified as novel inhibitors of human respiratory syncytial virus infection .
Front Cell Infect Microbiol
January 2025
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Introduction: Respiratory syncytial virus (RSV) remains a major international public health concern. However, disease treatment is limited to preventive care with monoclonal antibodies and supportive care. In this study, natural products were screened to identify novel anti-RSV inhibitors.
View Article and Find Full Text PDFSpirochrains A-D, Four Caged [5,6,5] Spirocyclic Amides from an Antarctic Fungus SCSIO 05702 with Anti-RSV Activities.
Org Lett
January 2025
CAS Key Laboratory of Tropical Marine Bio-resources and Ecology/Guangdong Key Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China.
Spirochrains A-D, four undescribed spirocyclic amides, were obtained from an Antarctic fungus, SCSIO 05702. Their structures were elucidated through spectroscopic analysis and quantum calculations. Spirochrains A-D possess a rarely reported cage-like 5/6/5 fused spirocyclic amide scaffold.
View Article and Find Full Text PDFRSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial.
BMC Infect Dis
December 2024
Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease among infants and young children worldwide, especially in low- and middle-income countries (LMICs). RSM01 is a novel, highly potent, half-life-extended anti-RSV monoclonal antibody (mAb) candidate primarily being developed for LMICs. Here we present the preclinical characterisation and results of a phase 1 trial of RSM01.
View Article and Find Full Text PDFNetwork pharmacology, molecular docking, and untargeted metabolomics reveal molecular mechanisms of multi-targets effects of Qingfei Tongluo Plaster improving respiratory syncytial virus pneumonia.
Chin Herb Med
October 2024
Graduate School, Liaoning University of Traditional Chinese Medicine, Shenyang 110032, China.
Objective: Qingfei Tongluo Plaster (QFP), an improved Chinese medicine hospital preparation, is an attractive treatment option due to its well clinical efficacy, convenience, economy, and patient compliance in the treatment of respiratory syncytial virus (RSV) pneumonia. The aim of this study was to investigate the efficacy mechanism of QFP on RSV rats from the perspective of alleviating lung inflammation and further explore the changes of serum metabolites and metabolic pathways in RSV rats under the influence of QFP.
Methods: This study used network pharmacological methods and molecular docking combined with molecular biology and metabolomics from multi-dimensional perspectives to screen and verify the therapeutic targets.
Antiviral Peptide-Generative Pre-Trained Transformer (AVP-GPT): A Deep Learning-Powered Model for Antiviral Peptide Design with High-Throughput Discovery and Exceptional Potency.
Viruses
October 2024
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., Beijing 100176, China.
Traditional antiviral peptide (AVP) discovery is a time-consuming and expensive process. This study introduces AVP-GPT, a novel deep learning method utilizing transformer-based language models and multimodal architectures specifically designed for AVP design. AVP-GPT demonstrated exceptional efficiency, generating 10,000 unique peptides and identifying potential AVPs within two days on a GPU system.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!